for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sinovac Biotech Ltd.

SVA.A

Latest Trade

6.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.92

 - 

6.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.47
Open
--
Volume
--
3M AVG Volume
0.00
Today's High
--
Today's Low
--
52 Week High
6.92
52 Week Low
6.92
Shares Out (MIL)
71.52
Market Cap (MIL)
639.90
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2021 Sinovac Biotech Ltd Earnings Release

Latest Developments

更多

Sinovac Receives Approval On Sabin Strain Based Inactivated Polio Vaccine (Sipv) To Support Global Polio Endgame Strategy

Interim Analysis From Phase 3 Trial Suggests Efficacy Of 2 Doses Of CoronaVac Is 83.5% Against Symptomatic COVID-19- The Lancet

The Lancet Infectious Diseases Published Data From Sinovac’s Phase I/Ii Study, World’S First Published Study On Clinical Trial Results Of A Covid-19 Vaccine In Healthy Children And Adolescents A

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sinovac Biotech Ltd.

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Industry

Biotechnology & Drugs

Contact Info

39 Shangdi Xi Road, Haidian District

BEIJING, BEJ

102200

China

+86.10.56931800

http://www.sinovac.com/

Executive Leadership

WeiDong Yin

Chairman of the Board, President, Chief Executive Officer, Secretary

Nan Wang

Chief Financial Officer, Vice President

Qiang Gao

Chief Operating Officer, Vice President

Jing Li

Vice President - Quality and Production

Simon J. Anderson

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.25
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
3.49
Total Debt To Equity (MRQ)
6.35
LT Debt To Equity (MRQ)
1.11
Return on Investment (TTM)
32.07
Return on Equity (TTM)
15.74

Latest News

Latest News

CORRECTED-UK to add China's Sinovac, India's Covaxin to approved vaccine list

Britain said it would recognise COVID-19 vaccines on the World Health Organization's Emergency Use Listing later this month, adding China's Sinovac, Sinopharm and India's Covaxin to the country's approved list of vaccines for inbound travellers.

Rebuffed by Bolsonaro, Brazil medical institute to sell vaccines abroad

Brazil's Butantan biomedical institute is in talks to sell a locally manufactured COVID-19 vaccine developed by China's Sinovac to other countries in South America and Africa, as the federal government has not ordered more of the shots.

Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Sinovac alone -study

A Chinese study https://www.medrxiv.org/content/10.1101/2021.09.03.21263062v1.supplementary-material looking at mixing COVID-19 vaccines showed that receiving a booster shot of CanSino Biologics' vaccine after one or two doses of Sinovac Biotech's vaccine yielded a much...

WHO begins shipping Chinese vaccines despite some misgivings

* COVAX starts delivering 100 mln Sinovac and Sinopharm doses

CORRECTED-UPDATE 2-Antibodies from Sinovac's COVID-19 shot fade after about 6 months, booster helps - study

Antibodies triggered by Sinovac Biotech's COVID-19 vaccine declined below a key threshold from around six months after a second dose for most recipients, but a third shot had a strong booster effect, a lab study showed.

UPDATE 1-China's Sinovac to invest $60 mln in vaccine facility in Chile

Chinese pharmaceutical Sinovac Biotech Ltd on Wednesday said it will build a fill-and-finish vaccine plant in Chile with an investment of $60 million, consolidating its presence in the Latin American nation that has used its COVID-19 shot the most.

China's Sinovac to invest $60 mln in vaccine facility in Chile

Chinese pharmaceutical Sinovac Biotech Ltd on Wednesday said it will build a fill-and-finish vaccine plant in Chile with an investment of $60 million, consolidating its presence in the Latin American nation that has used its COVID-19 shot the most.

Antibodies from Sinovac's COVID-19 shot fade after about 6 months, booster helps - study

Antibodies triggered by Sinovac Biotech's COVID-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.

China's Sinovac evaluates vaccine plant in Chile

Chilean authorities said on Friday that China's Sinovac had begun evaluating potential sites for the construction of a vaccine plant in Chile that could begin producing doses of the Chinese shot as early as the first half of 2022.

REFILE-Sinovac's vaccine finds supporters in Singapore despite effectiveness questions elsewhere

Sinovac's COVID-19 vaccine, under growing scrutiny over its effectiveness, has found a small but determined group of takers in Singapore - even though the country does not count them as being vaccinated in its official tally.

UPDATE 2-Hundreds of vaccinated Indonesian health workers get COVID-19, dozens in hospital

More than 350 doctors and medical workers have caught COVID-19 in Indonesia despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns grow about the efficacy of some vaccines against more infectious variants.

Sinovac, Pfizer/BioNtech COVID-19 vaccines prove highly effective in Uruguay -government

Uruguay on Tuesday released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths.

UPDATE 2-WHO approves Sinovac COVID shot in second Chinese milestone

The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, paving the way for a second Chinese shot to be used in poor countries.

WHO approves Sinovac COVID-19 vaccine, 2nd Chinese-made dose listed

The World Health Organization (WHO) has approved a COVID-19 vaccine made by Sinovac Biotech for emergency use listing, the second Chinese-produced shot to get its endorsement, a WHO statement said on Tuesday.

UPDATE 1-Brazil to halt Sinovac vaccine production as Chinese supplies held up

Brazil will run out of raw materials to produce Sinovac Biotech Ltd's COVID-19 vaccine by Friday, as a supply shipment has been held up in Chinese export clearance, authorities in the state of Sao Paulo said on Wednesday.

UPDATE 1-EU regulator begins real-time review of first Chinese COVID-19 vaccine

Europe's medicines regulator said on Tuesday it has started a real-time review of Sinovac's COVID-19 vaccine, based on preliminary results from animal and human trials that suggested the vaccine produces an immune response against the coronavirus.

EU drug regulator begins real-time review of Sinovac's COVID-19 vaccine

Europe's medicines regulator said on Tuesday it has started a real-time review of Sinovac's COVID-19 vaccine, based on preliminary results from animal and human trials that suggested the vaccine produces an immune response against the coronavirus.

WHO sets dates for reviews of Sinopharm and Sinovac COVID-19 vaccines

Technical experts at the World Health Organization (WHO) will review on April 26 Chinese drugmaker Sinopharm's COVID-19 vaccine for possible emergency use listing, to be followed by the Sinovac jab on May 3, the agency said on Thursday.

ANALYSIS-Chile's COVID-19 vaccine drive shifts to second doses over protection, supply concerns

Chile is shifting its COVID-19 vaccination strategy toward issuing second doses, while slowing administration of new shots, due to concerns over supply shortages and data showing scant protection from one dose of the Sinovac Biotech vaccine that formed the backbone of its...

UPDATE 1-Sinopharm, Sinovac COVID-19 vaccine data show efficacy - WHO

Chinese vaccine makers Sinopharm and Sinovac have presented data on their COVID-19 vaccines indicating levels of efficacy that would be compatible with those required by the World Health Organization, the chair of a WHO advisory panel said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up